Guidance

National protocol for COVID-19 Vaccine AstraZeneca (ChAdOx1-S [recombinant])

This protocol is for the administration of COVID-19 Vaccine AstraZeneca (ChAdOx1-S [recombinant]) to individuals in accordance with the national COVID-19 vaccination programme.

• From: UK Health Security Agency
• Published: 10 January 2021
• Last updated: 1 April 2022
  Show all updates

  1. 1 April 2022

     Removed expired protocol (v06.00).

  2. 29 March 2022

     Added v07.00 – expiry extension of v06.00.

  3. 16 February 2022

     Added version 6 – see page 4 for change history.

  4. 29 October 2021

     Added version 5 – see page 3 for change history.

  5. 17 May 2021

     Added version 4 - see page 3 for change history.

  6. 27 April 2021

     Added version 3 - see page 3 for change history.

  7. 14 April 2021

     Added version 02.00.

  8. 10 January 2021

     First published.

This publication was withdrawn on 29 June 2022

This product is no longer in use in the UK. Please refer to the National protocol for Vaxzevria COVID-19 Vaccine (ChAdOx1-S [recombinant]).

Applies to England

Documents

[Withdrawn] National protocol for COVID-19 Vaccine AstraZeneca (ChAdOx1-S [recombinant]) (v07.00)

Ref: UKHSA gateway number GOV-11819

MS Word Document, 237 KB

This file may not be suitable for users of assistive technology.

Request an accessible format

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This protocol is for the administration of coronavirus (COVID-19) vaccine AstraZeneca (ChAdOx1-S [recombinant]) by appropriately trained persons.

National protocol for AstraZeneca (ChAdOx1-S [recombinant]) v07.00 is valid from 31 March 2022 to 1 October 2022.